A new standard of care for advanced lung cancer: what’s next for pembrolizumab?
Martin Reck • 11 Apr 2018
IMpower150: efficacy outcomes of atezolizumab addition in pre-treated EGFR-mutated NSCLC
Targeting Siglec-15 with NC318 in Siglec-15-positive advanced solid tumors
Omid Hamid • 12 Nov 2021